Sentences with phrase «negative breast cancer in women»

Now, University of Missouri researchers have found that luteolin, a natural compound found in herbs such as thyme and parsley, and vegetables such as celery and broccoli, could reduce the risk of developing metastasis originating from triple - negative breast cancer in women.

Not exact matches

An international, collaborative study of almost 37,000 breast cancer cases published in the Annals of Oncology in October 2015 found a 20 percent reduction in risk of developing hormone - receptor negative breast cancer for women who breastfed.

The MINDACT study is managed and sponsored by the EORTC in collaboration with the Breast International Group (BIG) and included 6,693 women with early stage breast cancer (lymph node negative or 1 - 3 lymph node posiBreast International Group (BIG) and included 6,693 women with early stage breast cancer (lymph node negative or 1 - 3 lymph node posibreast cancer (lymph node negative or 1 - 3 lymph node positive).

Weidhaas» most recent study, planned for release in December, suggests that hormone replacement therapy (HRT) itself is linked to triple - negative breast cancer in post-menopausal KRAS - variant women.

«Mayo Clinic is now developing new studies that will focus on the role of CDK 4/6 inhibitors and their potential to inhibit cancer metastasis in women with triple - negative breast cancer who are at highest risk for cancer metastasis.»

The NPV was 99.1 percent in women who had dense breasts and 99.3 in women with non-dense tissue, providing confirmation that when a woman receives a negative test result, she does not have breast cancer.

said Judith K. Wolf, MD, Chief Medical Officer of Provista Diagnostics, Inc. «This study shows that, with an over 99 percent negative predictive value (NPV), clinicians can confidently use Videssa Breast to detect cancer in women with dense breasts and better determine when biopsy is truly warranted to assess suspicious findings.»

A team including scientists at The Institute of Cancer Research, London, found that women whose breast cancer had begun to spread and who tested positive in the αB - crystallin test were three times more likely to have disease that spread to the brain than those who tested negCancer Research, London, found that women whose breast cancer had begun to spread and who tested positive in the αB - crystallin test were three times more likely to have disease that spread to the brain than those who tested negcancer had begun to spread and who tested positive in the αB - crystallin test were three times more likely to have disease that spread to the brain than those who tested negative.

The study involved women with axillary node - positive (cancer in the lymph glands under the arm) or high - risk node - negative breast cancer (no cancer in under arm nodes, but cancer with bad prognostic features).

Women with very high immunoCRIT even have a triple increase in their risk of developing estrogen - receptor negative breast cancer.

It has been recognized that the more aggressive triple - negative breast cancer occurs more frequently in African American women, but no previous study has examined racial differences in tumor genotype and how they might contribute to the risk of cancer recurrence.

«In addition to having a higher prevalence of triple - negative breast cancers than Caucasian women — something that has been documented in previous studies — we found that African American women with breast cancer had a significantly higher prevalence of the TP53 driver mutation, basal tumor subtype and greater genomic diversity within tumors, all of which suggest more aggressive tumor biology,» says Tanya Keenan, MD, of the MGH Cancer Center, lead author of the studIn addition to having a higher prevalence of triple - negative breast cancers than Caucasian women — something that has been documented in previous studies — we found that African American women with breast cancer had a significantly higher prevalence of the TP53 driver mutation, basal tumor subtype and greater genomic diversity within tumors, all of which suggest more aggressive tumor biology,» says Tanya Keenan, MD, of the MGH Cancer Center, lead author of the studin previous studies — we found that African American women with breast cancer had a significantly higher prevalence of the TP53 driver mutation, basal tumor subtype and greater genomic diversity within tumors, all of which suggest more aggressive tumor biology,» says Tanya Keenan, MD, of the MGH Cancer Center, lead author of the cancer had a significantly higher prevalence of the TP53 driver mutation, basal tumor subtype and greater genomic diversity within tumors, all of which suggest more aggressive tumor biology,» says Tanya Keenan, MD, of the MGH Cancer Center, lead author of the Cancer Center, lead author of the study.

Triple negative breast cancers tend to occur more often in younger women and in African - American women.

About the Prosigna ® Breast Cancer Prognostic Gene Signature Assay and nCounter ® Dx Analysis System The Prosigna Assay provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node - negative (Stage I or II) or node - positive (Stage II), hormone receptor - positive (HR +) breast cBreast Cancer Prognostic Gene Signature Assay and nCounter ® Dx Analysis System The Prosigna Assay provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node - negative (Stage I or II) or node - positive (Stage II), hormone receptor - positive (HR +) breast cCancer Prognostic Gene Signature Assay and nCounter ® Dx Analysis System The Prosigna Assay provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node - negative (Stage I or II) or node - positive (Stage II), hormone receptor - positive (HR +) breast cbreast cancercancer.

In an article published in the Journal of Clinical Oncology (https://doi.org/10.1200/JCO.2017.74.6586), Laenkholm et al report on a study of 2,558 postmenopausal women identified as having HR positive / HER2 - negative, early - stage breast cancer, 1,395 of whom had one to three positive axillary nodeIn an article published in the Journal of Clinical Oncology (https://doi.org/10.1200/JCO.2017.74.6586), Laenkholm et al report on a study of 2,558 postmenopausal women identified as having HR positive / HER2 - negative, early - stage breast cancer, 1,395 of whom had one to three positive axillary nodein the Journal of Clinical Oncology (https://doi.org/10.1200/JCO.2017.74.6586), Laenkholm et al report on a study of 2,558 postmenopausal women identified as having HR positive / HER2 - negative, early - stage breast cancer, 1,395 of whom had one to three positive axillary nodes.

«These results have driven us to update our treatment guidelines in Denmark to include testing with Prosigna as part of the workup of postmenopausal women with early stage HR - positive / Her -2 negative breast cancer, including patients with node - positive disease.»

SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andBreast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andCancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andbreast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.

â $ Experiencing more than one [negative] meaningful life event... is a risk factor for breast cancer among young women, â $ the authors, from Ben - Gurion University of the Negev in Beer Sheva and Haifa University in Haifa, Israel, wrote.

Many women are «triple negative» No one yet knows precisely why, but African - American women are roughly twice as likely as white women to have triple - negative breast cancer — so called because tumor cells in this particularly aggressive form of the disease test negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER - 2).

Triple - negative cancer is the most common type of breast cancer found in women with changes in a gene called BRCA1.

«CONCLUSIONS: A high daily intake of coffee was found to be associated with a statistically significant decrease in ER - negative breast cancer among postmenopausal women.»

Sesame seeds contain relatively high levels of copper, which could contribute to angiogenesis and metastasis of breast cancer, especialy in women with inflammatory breast cancer (IBC) or triple negative (ER - / PR - / HER2 --RRB- disease.

Yet in South Korean, where kimchi is eaten at several meals each day, women have a very low rate of breast cancer: https://healthcaredelivery.cancer.gov/icsn/breast/mortality.html Might be that they have a good diet that counteracts the negatives of kimchi, or the studies could be flawed.

But abdominal fat in particular has its own risks: Pre-menopausal women with a large waist are more likely to develop breast cancer that is estrogen receptor (ER)- negative, according to a study in the Journal of the National Cancer Instcancer that is estrogen receptor (ER)- negative, according to a study in the Journal of the National Cancer InstCancer Institute.